

Help your patients Go Beyond Expectations in psoriatic disease



We've consulted patient groups to find out what psoriasis (Pso) or psoriatic arthritis (PsA) resources could help them, beyond their valuable time with you.

Discover credible information to support the care you provide

- A refresh of the basics about their condition
- Different treatments available, and what helps inform your prescribing decision
- Tips for body and mind when living with Pso or PsA
- How to optimise the time they have with you
- FAQs answered
- Useful downloads, including progress tracker sheets

We're here to support you and your patients on the journey towards better health, one step and triumph at a time.

Go Beyond Expectations today >

www.janssenwithme.com/beyond-expectations



Little wins in psoriatic disease start here



PHARMACEUTICAL COMPANIES OF
Johnson & Johnson

EM-91228 March 2022

REVIEW ARTICLE

The use of lasers in vitiligo, an overview

N.F. Post,^{1,*}  N. Ezekwe,² V.S. Narayan,¹  M.W. Bekkenk,¹ N. Van Geel,³  I. Hamzavi,² T. Passeron,⁴ A. Wolkerstorfer¹

¹Department of Dermatology, Amsterdam University Medical Centers, Amsterdam, The Netherlands

²Department of Dermatology, Henry Ford Health System, Detroit, MI, USA

³Department of Dermatology, Ghent University Hospital, Ghent, Belgium

⁴Department of Dermatology and INSERM U1065, University Hospital of Nice, Nice, France

*Correspondence: N.F. Post. E-mail: n.f.post@amsterdamumc.nl

Abstract

Various types of lasers have been demonstrated to be effective in the treatment of vitiligo. The mode of action of these lasers is just as varied as the purpose of intervention. Many clinicians are not aware of the unique opportunity these lasers offer to improve the outcomes of vitiligo treatment. To date, no clear overview exists of the use of lasers in vitiligo treatment. Thus, the aim of this review is to discuss the various types of lasers and provide an overview of the evidence for their efficacy. We found good evidence from a systematic review that the excimer laser is effective, induces repigmentation rates comparable to NB-UVB and has improved outcomes when combined with calcineurin inhibitors. Ablative lasers are commonly used for tissue graft or melanocyte–keratinocyte cell graft transplantation. They provide safe, fast and uniform denudation of the epidermis with propitious repigmentation outcomes. We found conflicting evidence from two systematic reviews regarding the efficacy of fractional ablative lasers for improving outcomes of NB-UVB therapy, a systematic review including only fractional ablative lasers provided evidence for efficacy. Q-switched nanosecond lasers have shown to be safe and effective for inducing depigmentation, although recurrence is common, and most studies were small and retrospective. Despite proven efficacy and safety, laser treatments are relatively expensive and suited for limited body surface areas and selected cases. Each type of laser has benefits and risks associated and should, therefore, be individually chosen based on location, extent, activity and type of vitiligo.

Received: 4 August 2021; revised: 10 December 2021; Accepted: 3 February 2022

Conflicts of interest

None declared.

Funding sources

None.

Introduction

Vitiligo is a psychologically impairing autoimmune disorder inducing skin depigmentation that affects 0.2–1.8%¹ of the population and has a major impact on the quality of life.² The mainstay of treatment consists of topical/systemic immunosuppressant's and phototherapy, which serve to stabilize depigmented lesions and to stimulate repigmentation in both stable and unstable vitiligo. Tissue graft or melanocyte–keratinocyte cell graft transplantation (MKT) provides a more definitive surgical option for patients with stable and localized vitiligo or with segmental vitiligo who have failed repigmentation, despite topical treatments and light therapy. In addition, various types of lasers, used as both monotherapy and combination therapy, have been demonstrated to be effective in the treatment of vitiligo. The mode of action of these lasers is just as varied as the purpose of intervention and involves photo biomodulation for

repigmentation (excimer lasers), photo ablation for recipient site preparation before grafting (ablative lasers), tissue stimulation to enhance efficacy of phototherapy (fractional lasers) and photo mechanic interactions for depigmentation (Q-switched lasers). Many clinicians are not aware of the various types of lasers that improve the outcomes of vitiligo treatment. Therefore, we aim to discuss the various types of lasers used in vitiligo and the evidence for their efficacy.

Excimer laser

The 308-nm excimer laser (EL), a targeted phototherapy device, was first described in 2002 for repigmentation of vitiligo.³ The EL emits coherent and monochromatic light at 308 nm, which is adjacent to 311 nm narrowband-UVB (NB-UVB) and has similar effects. It is indicated for depigmented body surface areas (BSA) <10% and has the advantage of not affecting surrounding

skin.² Similar to NB-UVB, the EL inhibits inflammation and induces T-cell apoptosis. In addition, the EL induces the differentiation of melanocyte stem cells, stimulates the production of melanin and the proliferation and migration of melanocytes inducing repigmentation.⁴ There is strong evidence demonstrating the efficacy of EL in treating non-segmental vitiligo.⁵

The efficacy of EL has been compared to the 308-nm excimer lamp and 311-nm NB-UVB in two meta-analyses.^{5,6} Based on three randomized controlled trials (RCTs),^{7–9} a meta-analysis found no difference between EL and excimer lamp in achieving $\geq 50\%$ and $\geq 75\%$ repigmentation. Similarly, no difference was found in patients achieving $\geq 75\%$ and 100% repigmentation between EL and NB-UVB in a meta-analysis based on four RCTs.^{10–13} Nevertheless, EL was more effective than NB-UVB when assessing $\geq 50\%$ repigmentation as an outcome. Another study assessed non-segmental vitiligo patients treated with either EL or NB-UVB after punch grafting and showed no significant difference in repigmentation.¹⁰

A recently developed 311-nm titanium sapphire laser was shown not to be inferior to EL treatment in a randomized non-inferiority study with 74 paired lesions in 21 patients.¹⁴ Another meta-analysis¹³ assessed the benefit of adding topical therapy to EL and showed superior repigmentation for combination therapy with calcineurin inhibitors,^{15–18} however, insufficient evidence was found for combination therapy with topical vitamin D3^{19–21} analogues and corticosteroids.²² Furthermore, the efficacy of EL with topical tacrolimus was assessed in the meta-analysis of Chang.²³ Three RCTs^{15,16,18} showed better improvements for $\geq 75\%$ repigmentation when EL was combined with topical tacrolimus compared to EL alone. This was in line with the Cochrane review on vitiligo about combining NB-UVB phototherapy with topical interventions.²⁴ Moreover, a RCT with 233 paediatric vitiligo patients showed better results after twelve weeks of treatment with EL combination therapy (tacrolimus, pimecrolimus or halometasone) compared to EL monotherapy.²⁵ Wu *et al* compared EL monotherapy to tacrolimus 0.1% topical monotherapy and found no difference in $\geq 50\%$ repigmentation after 6 months.²⁶

There is insufficient evidence about the optimal regimen of EL therapy. One randomized, non-inferiority study showed a cyclic schedule (two months, twice weekly, one-month interval) to be equally effective compared to a continuous schedule of EL twice per week.²⁷ This cyclic schedule may favour compliance and limits UV exposure. Moreover, no significant differences were found between one, two or three sessions per week.^{28,29} However, repigmentation was faster with three sessions per week.²⁸ According to the relationship between repigmentation and the total number of treatments, a minimum of 20 treatments is recommended.¹⁷ Inferior repigmentation was related to a longer disease duration, the presence of poliosis, location of lesions on hands and feet and a plurisegmental pattern. Facial lesions and younger patients were related to better outcomes.^{30–32}

Multiple studies have proven the efficacy and safety of both EL and excimer lamps (together excimer therapy) in localized, non-segmental vitiligo.^{7–9} The repigmentation rate and side-effect profile are comparable to NB-UVB phototherapy, which should be reserved for patients with more than 5–10% BSA.^{3,5,6} The excimer lamp provides the same efficacy and is more cost-effective. Disadvantages of EL are the high costs for acquisition and maintenance, limited availability, and the laborious nature of procedures. Advantages of EL include the lower total cumulative UV dose compared to NB-UVB, lack of exposure of unaffected skin and high efficacy especially when combined with calcineurin inhibitors.^{10,15–18}

The efficacy of the excimer laser as adjuvant therapy following graft transplantation was assessed in two controlled trials. Firstly a comparative trial with 14 stable NSV patients treated with punch grafts showed no difference in repigmentation rate after adjuvant therapy with either EL or NB-UVB.¹⁰ Ebadi *et al.*³³ showed in a non-randomized clinical trial with 10 stable NSV patients a difference between melanocyte-keratinocyte transplantation (MKT) and excimer laser combination therapy compared to excimer laser or MKT alone.

In summary, the combination of excimer therapy with topical immunosuppressive treatment is recommended in localized, non-segmental and segmental vitiligo. The safety of this therapy has been demonstrated recently in a large cohort of 25 694 vitiligo patients.³⁴ However, in active vitiligo with BSA > 10%, the combination of oral mini-pulse therapy and NB-UVB was favored.³⁵

Lasers used for melanocyte transplantation

There are multiple methods used for recipient site preparation in MKT such as liquid nitrogen, dermabrasion, psoralen ultraviolet A, suction blistering and lasers.³⁶ Recipient site preparation is essential as it affects the adherence of the melanocyte graft, nutritional support for the graft, final repigmentation rate, aesthetic outcome and associated complications of the transplantation. Lasers, as opposed to other methods of recipient-site preparation, can be used on larger surface areas, delicate areas and cosmetically compromised areas such as the mouth, nose and eyelids without harming surrounding skin.³⁷ Moreover, laser treatments can be standardized yielding highly reproducible effects, especially when using scanner devices. However, lasers are generally expensive, may increase the risk of dyspigmentation, and have attendant risk of scarring.³⁸ Lasers, when appropriately handled, can offer control of depth and symmetry of the extirpated sites.

Short-pulsed carbon dioxide (CO₂) laser for recipient preparation

The short-pulsed CO₂ laser emits short bursts of high-energy 10 600-nm radiation, producing fast tissue ablation with minimal bleeding. Moreover, it induces less thermal damage to the surrounding tissues compared to the older, conventional

continuous wave CO₂ laser, that has a higher risk of scarring.^{39,40} Modification with integrated scanner device provides more precise and uniform de-epithelialization with greater user reproducibility.⁴¹ Treatment with such a short-pulsed CO₂ laser and scanner to the preparation site produced > 80% repigmentation in several MKT studies.^{40,42,43} An open, split-comparison study in stable vitiligo compared repigmentation results of mechanical dermabrasion to short-pulsed CO₂ laser (82% density, 209- μ m depth) for recipient site preparation. Overall, the dermabrasion seemed to have better repigmentation, although one patient developed hypertrophic scarring and atrophy at the dermabrasion site.³⁸

Erbium YAG (Er:YAG) laser for recipient preparation

The Erbium-doped Yttrium Aluminium Garnet (Er:YAG) laser emits 2940-nm radiation which is absorbed by water approximately 10 times more than the CO₂ radiation, reducing thermal damage and risk of scarring.^{36,44} Gupta *et al.*⁴⁵ evaluated the use of Er:YAG laser vs. motorized dermabrader in recipient site preparation in a RCT with 32 patients. No difference in repigmentation or adverse events were seen.

Lagrange *et al.* compared microneedling to Er:YAG laser in a RCT with 6 patients.⁴⁶ Three patients showed > 75% repigmentation, while none achieved any repigmentation with microneedling.^{46,47}

Finally, a long-term retrospective study with 714 patients reported that motorized dermabrasion had a lower recurrence rate than Er:YAG laser.⁴⁸ Limitations including laser user variability and the retrospective nature of the study may not allow to elucidate broader, more generalizable outcomes.

Fractional CO₂ laser for recipient preparation

A RCT compared full surface superficial ablation (144 μ m), deeper ablation (209 μ m) and fractional ablation (225 μ m) to negative control as a pretreatment for cell suspension transplantation.⁴⁷ More than 75% repigmentation was found in 40%, 50% and 0% of the superficial, deeper, and fractional ablation respectively. The authors concluded that superficial full surface ablation is effective while fractional ablation is not effective for recipient site preparation.

In summary, ablative lasers appear to provide fast and uniform denudation of the epidermis with propitious repigmentation outcomes for recipient site preparation. Only pulsed lasers should be used for recipient site preparation because of the risk of scarring with continuous wave lasers. Conventional, full surface ablation is more effective than the fractional ablation or microneedling. Generally, Er:YAG lasers are regarded to induce less thermal damage, scarring and dyspigmentation than CO₂ lasers. Moreover Er:YAG lasers offer a better assessment of the depth of the dermabrasion. Each choice of laser has benefits and risks associated and should

be individualized to the patient and resources available at the time of transplantation.

Fractional laser for enhancing UV-induced repigmentation

Conventional ablative lasers, such as the CO₂ laser and Er:YAG laser, have been reported to enhance repigmentation when combined with NB-UVB.⁴⁹ However, these lasers have significant downtime and risk of scarring.

More recently, fractional ablative lasers offer less side-effects and have been reported to be effective when combined with NB-UVB.⁵⁰

Unlike conventional ablative lasers, fractional lasers treat only a 'fraction' of the affected skin by creating microscopic thermal zones (MTZ) leaving intervening areas of skin untreated and results in rapid re-epithelialization of the skin.^{51,52} These 'micro-wounds' induce pro-inflammatory cytokines and growth factors, which not only promote rejuvenation and regeneration but also proliferation and migration of melanocytes.⁵²⁻⁵⁴ Fractional CO₂ lasers also produce immediate tissue contraction and thereby temporarily reduce the vitiligo lesion size.⁵⁵

In 2020, two systematic reviews with meta-analyses were published evaluating the safety and efficacy of fractional CO₂ laser as an add-on therapy for NB-UVB.^{56,57} Firstly, Kim *et al.* conducted a meta-analysis with 3 RCTs, comparing NB-UVB monotherapy and CO₂ laser combined with NB-UVB therapy, excluding any other treatment methods.⁵⁸⁻⁶⁰ They demonstrated a higher repigmentation rate from combination therapy compared to NB-UVB alone. In contrast, Chang *et al.* published a meta-analysis involving 6 RCTs^{53,58-62} showing a non-significant trend in favour of the CO₂ laser and NB-UVB combination therapy. However, additional treatments (i.e. surgery, hair transplantation, topical agents) were included. Moreover, some of the contradictory results may be explained by the various degrees of disease stability in different studies.

King *et al.*⁶³ demonstrated NB-UVB treatment for vitiligo was more effective when combined with ablation therapy in a systematic review and meta-analysis. However, these results can be interpreted in an ambiguous manner, as conventional ablative and fractional ablative lasers were pooled in the same meta-analysis while they are fundamentally different modalities.^{51,52}

In summary, based on the available literature, fractional ablative lasers are a safe option to improve the outcomes of NB-UVB. No severe side-effects from fractional therapy were reported and the Koebner phenomenon was not observed. A young age (< 14 years), short disease duration (< 1 year), stable disease and vitiligo on head and neck resulted in significantly better repigmentation.^{64,65} However, the treatment is uncomfortable, time consuming and only feasible for relatively small areas (< 3% BSA) (Table 1).

Table 1 Description of laser type, treatment protocol and outcomes

First Author, Year, ref	Laser type, wavelength	(sub)type vitiligo	Study design	Number of patients/patches	Monotherapy/combination therapy	Treatment compared to	Outcomes, results
Baltás, 2002 ³	Excimer laser 308 nm	Segmental, focal	Case series	6 patients	Monotherapy	–	Percentage achieving $\geq 75\%$ repigmentation 50%
Sun, 2015 ⁵	Excimer laser 308 nm	NSV	Systematic review	390 patients/764 patches	Monotherapy	Excimer lamp ⁷⁻⁹ NB-UVB ¹⁰⁻¹³	Percentage achieving $\geq 75\%$ repigmentation EL 54.35% vs. NB-UVB 51.51% EL 34.87% vs. excimer lamp 33.33%
Bae, 2019 ¹⁴	Excimer laser 308-nm	NSV	Non-inferiority RCT	21 patients/74 paired patches	Monotherapy	311-nm Titanium:Sapphire laser (TSL)	Mean repigmentation EL 55.4% TSL 58.2%
Bae, 2016 ³⁰ Chang, 2021 ²³	Excimer laser 308 nm	NSV	Systematic review	128 patients + 231 patches	Monotherapy	308-nm excimer laser + topical calcineurin inhibitors ¹⁵⁻¹⁸ / vitamin D3 analogues ¹⁹⁻²¹ / Topical corticosteroids ²²	Percentage achieving $\geq 75\%$ repigmentation EL 23.8% vs. EL + calcineurin inhibitors 46.2%* EL 2.9% vs. EL + vitamin D3 analogues 13.2%* EL 16.7% vs. EL + corticosteroids 42.9*
Li, 2019 ²⁵	Excimer laser 308 nm	NSV	RCT	233 paediatric patients	Monotherapy	308-nm excimer laser + tacrolimus/pimecrolimus/halometasone	Mean repigmentation EL monotherapy 57.7% EL + tacrolimus 76.6%* EL + pimecrolimus 72.9%* EL + halometasone 84.1%*
Wu, 2019 ²⁶	Excimer laser 308 nm	NSV	RCT	138 patients	Monotherapy	0.1% tacrolimus ointment (+ betamethasone i.m. for active vitiligo)	Percentage achieving $\geq 50\%$ repigmentation Stable vitiligo EL 47.5% vs. 0.1% tacrolimus 35% Active vitiligo EL 80.7%* vs. 0.1% tacrolimus 50%
Sung, 2018 ²⁷	Excimer laser 308 nm	NSV	Non-inferiority RCT	12 patients/16 paired patches	Combination therapy + 0.1% tacrolimus ointment	Continuous vs. Cyclic on-off	Mean repigmentation Continuous EL 51.4% Cyclic on-off EL 49.2%
Hofer, 2005 ²⁸	Excimer laser 308 nm	NSV	Prospective study	13 patients	Monotherapy 1, 2 and 3 sessions per week	–	Repigmentation 1 session per week 60% 2 sessions per week 79% 3 sessions per week 82%

Table 1 Continued

First Author, Year, ref	Laser type, wavelength	(sub)type vitiligo	Study design	Number of patients/patches	Monotherapy/combination therapy	Treatment compared to	Outcomes, results
Shen, 2007 ²⁹	Excimer laser 308 nm	NSV	Prospective study	187 patients	Monotherapy 20 sessions 0.5, 1, 2 and 3 sessions per week	–	Percentage achieving $\geq 75\%$ repigmentation 0.5 session per week 0% 1 session per week 25% 2 sessions per week 26% 3 sessions per week 32%
Fa, 2017 ³¹	Excimer laser 308 nm	NSV	Prospective study	979 patients	Monotherapy	–	Repigmentation Mean 29.77%
Ebadi, 2015 ³³	Excimer laser 308 nm	NSV	RCT	39 patches	Monotherapy	MKT / MKT + excimer laser/no treatment	Depigmentation reduction No treatment 0% EL + MKT 43.9%*
Silpa-Archa 2016 ³⁸	FCO2 laser 10 600 nm	NSV, local	Open label split comparison study	6 patients	Combination therapy + MKT	Dermabrasion + MKT	Reduction of VASI Dermabrasion VASI 84% FCO2 VASI 73.5%
Oh, 2001 ⁴⁰	Ultrapulsed CO2 laser 10 600 nm	NSV, local, focal	Case series	11 patients / 34 patches	Combination therapy + MKT + topical or general PUVA	–	Repigmentation Good (51–75%) 4 patches / excellent (76–100%) 30 patches
Hasegawa 2007 ⁴²	Short-pulsed CO2 laser 10 600 nm	Segmental	Case series	15 patients	Combination therapy + MKT	–	Repigmentation Mean 100%
Sun, 2012 ⁴³	Ultrapulsed CO2 laser 10 600 nm	NSV, segmental	Case series	8 patients	Combination therapy + MKT	–	Repigmentation Mean 84.4%
Kaufmann 1998 ⁴⁴	Erbium-YAG laser 2940 nm	NSV	Case series	3 patients / 9 patches	Combination therapy + MKT + UVA	–	Repigmentation 22% 'good' growth
Gupta, 2018 ⁴⁵	Er:YAG laser 2940 nm	NSV, focal, segmental	RCT	32 patients	Combination therapy + MKT	Mechanical dermabrasion + MKT	Total repigmentation Er:YAG + MKT 54.7% Dermabrasion + MKT 48.8%
Lagrange 2019 ⁴⁶	Er:YAG laser 2940 nm	Local, segmental	RCT	6 patients	Combination therapy + MKT	Microneedling + MKT	Percentage achieving $\geq 75\%$ repigmentation Er:YAG + MKT 16.7% Microneedling + MKT 0%

Table 1 Continued

First Author, Year, ref	Laser type, wavelength	(sub)type vitiligo	Study design	Number of patients/patches	Monotherapy/combination therapy	Treatment compared to	Outcomes, results
Lommerts 2017 ⁴⁷	Ablative CO2 laser 10 600 nm	Segmental	RCT	10 patients (3 vitiligo)	Combination therapy + MKT	209- μ m and 144- μ m full surface ablation + MKT/No treatment	Median repigmentation Fractional ablation 0% 209- μ m full surface ablation 68.7%* 144- μ m full surface ablation 58.3%*
Bayoumi 2012 ⁴⁹	Er:YAG laser 2940 nm	NSV	RCT	24 paired lesions	Combination therapy + hydrocortisone 17-butyrate cream + NB-UVB	Hydrocortisone 17-butyrate cream + NB-UVB	Percentage achieving \geq 50% repigmentation Dermabrasion + hydrocortisone 17-butyrate cream + NB-UVB: 45.9%* Hydrocortisone 17-butyrate cream + NB-UVB 8.4%
Kim, 2020 ⁵⁶	FCO2 laser 10 600 nm	NSV	SR	123 cases ⁵⁹⁻⁶⁰	Combination therapy + NB-UVB	NB-UVB	Percentage achieving \geq 75% repigmentation FCO2 + NB-UVB 8.1%* vs. NB-UVB 0.8%
Chang, 2020 ⁵⁷	FCO2 laser 10 600 nm	NSV	SR	140 patients ^{53,58-62}	Combination therapy + NB-UVB	NB-UVB	Percentage achieving \geq 75% repigmentation FCO2 + NB-UVB 10.6%* vs. NB-UVB 4.8%
Huang 2019 ⁶⁵	Er:YAG laser 2940 nm	NSV	Retrospective study	684 patients / 1,026 lesions	Combination therapy + laser-assisted delivery of topical compound betamethasone solution	–	Repigmentation Mean 40.3%
Kim, 2001 ⁷¹	QS ruby laser 694 nm	Vitiligo universals	Case report	1 patient	Combination therapy + Neoc-adjuvant PUVA	–	Relapse after complete depigmentation: no relapse after one year
Rao, 2004 ⁷²	QS alexandrite laser 755 nm	Vitiligo universals	Case report	1 patient	Monotherapy	–	Relapse after complete depigmentation: minimal recurrence of pigment

Table 1 Continued

First Author, Year, ref	Laser type, wavelength	(subtype vitiligo)	Study design	Number of patients/patches	Monotherapy/combination therapy	Treatment compared to	Outcomes, results
Majidi, 2013 ⁷³	Frequency-doubled QS Nd: YAG laser 532 nm	Vitiligo universalis	Prospective open-label study	15 patients / 26 patches	Combination therapy + Topical MBEH		Percentage achieving $\geq 90\%$ depigmentation 87.7% of patients
El-Mofty 2019 ⁷⁵	(Frequency-doubled) QS Nd: YAG laser 1s064/ 532 nm	Vitiligo universalis	Comparative study	40 patients	Monotherapy	Facial: TCA peels 25% and 50% Non-facial: cryotherapy, phenol 88%	Excellent/complete depigmentation Facial QSL 90%* vs. TCA peel 25 35% vs. TCA peel 50 60% Non-facial QSL 95% vs. cryotherapy 90% vs. phenol 100%
Majidi, 2017 ⁷⁶	Frequency-doubled QS Nd: YAG laser 532 nm	Vitiligo universalis	Retrospective study	28 patients	Monotherapy	–	Relapse after complete depigmentation: 25% of patients partial to complete relapse
Thissen 1997 ⁷⁷	QS ruby laser 694 nm	Vitiligo universalis	Open non-comparative clinical trial	8 patients	Monotherapy	–	Complete depigmentation in 37.5% of patients
Komen 2013 ⁷⁸	QS ruby laser 694 nm	Vitiligo universalis	Retrospective study	27 patients	Monotherapy	–	Percentage achieving $\geq 75\%$ depigmentation 48% of patients
Njoo, 2000 ⁷⁹	QS ruby laser 694 nm	Vitiligo universalis	Retrospective study	13 patients	Combination therapy + topical 4-methoxyphenol	–	Complete depigmentation in 69.2% of patients Recurrence of pigmentation in 44.4% of patients
Van Geel 2015 ⁸⁰	QS alexandrite laser 755 nm	Vitiligo universalis	Retrospective comparative study	22 patients / 51 patches	Monotherapy	Cryotherapy	Mean depigmentation after one session Cryotherapy 46.7% QS alexandrite 42.9%
Boukari 2014 ⁸¹	QS ruby laser 694 nm / QS alexandrite 755 nm / QS Nd: Yag 532 nm	Vitiligo universalis	Retrospective case series	6 patients / 16 patches	Monotherapy	–	Relapse after complete depigmentation 33% of patients/patches no relapse

$\geq 75\%$ of repigmentation was chosen to be presented in Table 1 when different repigmentation thresholds were reported.

* $P < 0.05$.

Lasers for depigmentation therapy in vitiligo

If depigmentation is non-responsive to treatment and extensive to nearly complete (vitiligo universalis), patients may wish to depigment the residual pigmented skin and thereby improve quality of life.⁶⁶ Topical bleaching treatments with monobenzyl ether of hydroquinone (MBEH),^{67,68} phenol peels,⁴ cryotherapy^{69,70} and lasers are all used as depigmenting treatment. Topical bleaching treatments are associated with limitations such as skin irritation, limited availability and incomplete and slow clinical response to achieve depigmentation.^{67,68} In comparison, lasers are relatively safer and more rapidly acting.^{71,72}

In general, Q-switched (QS) nanosecond lasers with various wavelengths (532, 694, 755 nm) have been used for depigmentation therapy. For picosecond lasers, evidence on efficacy for depigmentation is lacking so far. QS nanosecond lasers emit radiation with a high absorption by melanin and a very short pulse duration within the nanosecond range to match the thermal relaxation time of melanosomes. This results in a photomechanical laser tissue interaction leading to selective melanocyte damage.^{66,73,74}

Frequency-doubled QS neodymium-doped yttrium aluminium garnet (QS Nd:YAG) laser

Majid *et al.*⁷³ investigated the efficacy of the 532 nm QS Nd:YAG laser in a prospective open label study. Fifteen patients with > 80% depigmentation were treated 1–3 times. Thirteen of the 15 patients achieved $\geq 90\%$ depigmentation and only one patient reported recurrence at 3 months follow-up. Moreover, a RCT with 40 patients showed better outcomes for the face in patients with active vitiligo for the QS Nd:YAG laser as compared to TCA peeling.⁷⁵ Long-term depigmentation after QS Nd:YAG laser was evaluated in a retrospective study with 28 patients. After a follow-up period of 2–5 years, 85% of the patients were highly satisfied and 89.3% maintained depigmentation of > 90%.⁷⁶

QS ruby laser (QSRL)

Thissen *et al.*⁷⁷ achieved complete depigmentation in all 8 patients after 1 session using the QSRL. However, 5 patients developed follicular repigmentation during the 9-month follow-up. The other 3, all with initially positive Koebner phenomenon, remained depigmented on the treated areas. A retrospective study with 27 patients also evaluated the long-term efficacy of the QSRL after complete depigmentation was achieved. While only half of the patients showed > 75% depigmentation after a mean follow-up of 13 months, many patients (85%) were satisfied with the treatment.⁷⁸ Similar to other studies, active disease was related to better outcomes. Another retrospective study in nine QSRL-treated patients observed recurrence in almost half of the patients after 2–18 months.⁷⁹

QS alexandrite laser (QSAL)

Van Geel *et al.*⁸⁰ compared cryotherapy with the 755-nm alexandrite laser in 22 patients and found no significant difference in

the capacity to induce depigmentation (46.7% vs. 42.9%). However, side-effects were restricted to the group receiving cryotherapy.

Moreover a retrospective study with six patients with 16 normally pigmented skin areas with a BSA of 5–15% were treated with either 694 nm QS ruby laser, or 755 nm QS Alexandrite or 532 nm QS Nd:Yag laser until complete depigmentation with a median of two sessions. Two third of the patients had a relapse after a median follow-up of 36 months.⁸¹

In summary, laser-induced depigmentation therapy has proven to be a safe treatment with a high patient satisfaction.^{76,77,80} Short-term side-effects are common and include: purpura, crusts and oozing of the skin, but no long-term side-effects or scarring have been reported. Moreover, an advantage of laser therapy is that its effects are limited to the treatment site, while topical MBEH induces depigmentation in remote sites.⁶⁸ However, laser depigmentation is a painful treatment, for which topical anaesthesia is often necessary. The therapy is also time consuming, limiting the treatment area.⁷⁴ Long-term outcomes are highly variable and difficult to predict, besides in most cases maintenance sessions at least once a year are required. Active vitiligo and the presence of the Koebner phenomenon seem to be related to better depigmentation results.^{71,80} For these reasons, it is recommended to perform test spots prior to treatment. While there are no head-to-head comparisons between these QS laser devices, it is likely that the efficacy is more related to the activity of vitiligo than the type of laser device.

Summary

Lasers are an effective therapeutic option with a diversity of indications in vitiligo. These indications comprise repigmentation monotherapy, combination with NB-UVB, recipient site preparation before grafting and depigmentation. The laser devices that have been used are as diverse as the indications. When aiming for repigmentation, monotherapy with a 308 nm excimer or a 311 nm titanium sapphire laser is effective. The combination of the excimer laser with topical calcineurin inhibitors provides higher repigmentation rates. A minimum of 20 excimer laser sessions two or three times per week is recommended. Lasers for recipient site preparation can be used on large, delicate and cosmetically compromised areas in order to achieve reproducible ablation without harming surrounding skin. Short-pulsed CO₂ laser or Erb:YAG lasers should preferably be used, of which the Erb:YAG laser gives less thermal damage and a reduced risk of scarring. Fractional lasers improve the outcomes of repigmentation as an add-on therapy for NB-UVB. In universal vitiligo, Q-switched lasers are safe, rapidly acting and induce depigmentation in most of the patients although maintenance sessions are usually necessary.

The outcomes of laser treatment depend on many variables. High repigmentation rates after excimer laser treatment are more likely at a young age, with short disease duration and facial

localization. However, high depigmentation rates with QS lasers are best achieved when vitiligo is active with the presence of the Koebner phenomenon. Overall, patients are highly satisfied with the results and severe side-effects are very uncommon. Laser treatments can be standardized, yielding highly reproducible effects. Nonetheless all laser treatments are relatively expensive, not available in every hospital, not home based and only suited for small areas. Each type of laser has benefits and risks associated and should, therefore, be individually chosen based on location, extent, activity and type of vitiligo.

Data availability statement

Data sharing is not applicable to this article as no new data were created or analysed in this study.

References

- Zhang Y, Cai Y, Shi M *et al.* The prevalence of vitiligo: a meta-analysis. *PLoS One* 2016; **11**: 163806.
- Rodrigues M, Ezzedine K, Hamzavi I *et al.* Vitiligo Working Group. Current and emerging treatments for vitiligo. *J Am Acad Dermatol* 2017; **77**: 17–29.
- Baltás E, Csoma Z, Ignác F *et al.* Treatment of vitiligo with the 308-nm xenon chloride excimer laser. *Arch Dermatol* 2002; **138**: 1619.
- Goldberg DJ, Ellen ES, Schmults C *et al.* Histologic and ultrastructural analysis of ultraviolet B laser and light source treatment of leukoderma in striae distensae. *Dermatol Surg* 2011; **31**: 385–387.
- Sun Y, Wu Y, Xiao B *et al.* Treatment of 308-nm excimer laser on vitiligo: a systemic review of randomized controlled trials. *J Dermatolog Treat* 2015; **26**: 347–353.
- Lopes C, Trevisani VF, Melnik T. Efficacy and safety of 308-nm monochromatic excimer lamp versus other phototherapy devices for vitiligo: a systematic review with meta-analysis. *Am J Clin Dermatol* 2016; **17**: 23–32.
- Shi Q, Li K, Fu J *et al.* Comparison of the 308-nm excimer laser with the 308-nm excimer lamp in the treatment of vitiligo—a randomized bilateral comparison study. *Photodermatol Photoimmunol Photomed* 2013; **29**: 27–33.
- Le Duff F, Fontas E, Giaccherio D *et al.* 308-nm excimer lamp vs. 308-nm excimer laser for treating vitiligo: a randomized study. *Br J Dermatol* 2010; **163**: 188–192.
- Liu YB, Yang YF, Song LX *et al.* Comparison of 308 nm excimer laser and 308 nm excimer lamp in treatment of vitiligo. *Clin Misdiagnosis Mistherapy* 2013; **6**: 58–61.
- Linthorst HMW, Spuls PL, Nieuweboer-Krobotova L *et al.* A randomized comparison of excimer laser versus narrow-band ultraviolet B phototherapy after punch grafting in stable vitiligo patients. *J Eur Acad Dermatol Venereol* 2012; **26**: 690–695.
- Yang YS, Cho HR, Ryou JH, Lee MH. Clinical study of repigmentation patterns with either narrow-band ultraviolet B (NB-UVB) or 308 nm excimer laser treatment in Korean vitiligo patients. *Int J Dermatol* 2010; **49**: 317–323.
- Fei C, Gao Y. Clinical curative effect observation of 308-nm excimer laser treatment in stability of vitiligo. *China Med Abstracts* 2013; **30**: 342–343.
- Li YXL, Liu K, Xu L. Comparison between 308-nm excimer laser and NB-UVB on vitiligo. *Chin J Dermatol Venerol Integ Trad W Med* 2011; **10**: 181–182.
- Bae JM, Eun SH, Lee HN *et al.* Comparison of 311-nm Titanium: Sapphire laser and 308-nm excimer laser treatment for vitiligo: a randomized controlled non-inferiority trial. *Lasers Surg Med* 2019; **51**: 239–244.
- Kawalek AZ, Spencer JM, Phelps RG. Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. *Dermatol Surg* 2004; **30**: 130–135.
- Passeron T, Ostovari N, Zakaria W *et al.* Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. *Arch Dermatol* 2004; **140**: 1065–1069.
- Hui-Lan Y, Xiao-Yan H, Jian-Yong J, Zong-Rong L. Combination of 308-nm excimer laser with topical pimecrolimus for the treatment of childhood vitiligo. *Pediatr Dermatol* 2009; **26**: 354–356.
- Nistico S, Chiricozzi A, Saraceno R *et al.* Vitiligo treatment with monochromatic excimer light and tacrolimus: results of an open randomized controlled study. *Photomed Laser Surg* 2012; **30**: 26–30.
- Goldinger SM, Dummer R, Schmid P *et al.* Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligo. *J Eur Acad Dermatol Venereol* 2007; **21**: 504–508.
- Lu-yan T, Wen-wen F, Lei-hong X. Topical tacalcitol and 308-nm monochromatic excimer light: a synergistic combination for the treatment of vitiligo. *Photodermatol Photoimmunol Photomed* 2006; **22**: 310–314.
- Oh SH, Kim T, Jee H *et al.* Combination treatment of non-segmental vitiligo with a 308-nm xenon chloride excimer laser and topical high-concentration tacalcitol: a prospective, single-blinded, paired, comparative study. *J Am Acad Dermatol* 2011; **65**: 428–430.
- Sassi F, Cazzaniga S, Tessari G *et al.* Randomized controlled trial comparing the effectiveness of 308-nm excimer laser alone or in combination with topical hydrocortisone 17-butyrate cream in the treatment of vitiligo of the face and neck. *Br J Dermatol* 2008; **159**: 1186–1191.
- Chang HC, Sung CW. Efficacy of combination therapy of narrowband-ultraviolet B phototherapy or excimer laser with topical tacrolimus for vitiligo: an updated systematic review and meta-analysis. *Photodermatol Photoimmunol Photomed* 2021; **37**: 74–77.
- Whitton ME, Pinart M, Batchelor J *et al.* Interventions for vitiligo. *Cochrane Database Syst Rev* 2010;(1):CD003263.
- Li L, Liang Y, Hong J *et al.* The effectiveness of topical therapy combined with 308-nm excimer laser on vitiligo compared to excimer laser monotherapy in pediatric patients. *Pediatr Dermatol* 2019; **36**: e53–e55.
- Wu Y, Sun Y, Qiu L *et al.* A multicentre, randomized, split face and/or neck comparison of 308-nm excimer laser and 0.1% tacrolimus ointment for stable vitiligo plus intramuscular slow-releasing betamethasone for active vitiligo. *Br J Dermatol* 2019; **181**: 210–211.
- Sung JM, Bae JM, Kang HY. Comparison of cyclic and continuous 308-nm excimer laser treatments for vitiligo: a randomized controlled noninferiority trial. *J Am Acad Dermatol* 2018; **78**: 605–607.
- Hofer A, Hassan AS, Legat FJ *et al.* Optimal weekly frequency of 308-nm excimer laser treatment in vitiligo patients. *Br J Dermatol* 2005; **152**: 981–985.
- Shen Z, Gao TW, Chen L *et al.* Optimal frequency of treatment with the 308-nm excimer laser for vitiligo on the face and neck. *Photomed Laser Surg* 2007; **25**: 418–427.
- Bae JM, Hong BY, Lee JH *et al.* The efficacy of 308-nm excimer laser/light (EL) and topical agent combination therapy versus EL monotherapy for vitiligo: a systematic review and meta-analysis of randomized controlled trials (RCTs). *J Am Acad Dermatol* 2016; **74**: 907–915.
- Fa Y, Lin Y, Chi XJ *et al.* Treatment of vitiligo with 308-nm excimer laser: our experience from a 2-year follow-up of 979 Chinese patients. *J Eur Acad Dermatol Venereol* 2017; **31**: 337–340.
- Ostovari N, Passeron T, Zakaria W *et al.* Treatment of vitiligo by 308-nm excimer laser: an evaluation of variables affecting treatment response. *Lasers Surg Med* 2004; **35**: 152–156.
- Ebadi A, Rad MM, Nazari S *et al.* The additive effect of excimer laser on non-cultured melanocyte-keratinocyte transplantation for the treatment of vitiligo: a clinical trial in an Iranian population. *J Eur Acad Dermatol Venereol* 2015; **29**: 745–751.
- Ju HJ, Han JH, Kim MS *et al.* The long-term risk of lymphoma and skin cancer was not increased after topical calcineurin inhibitor use and phototherapy in a cohort of 25,694 patients with vitiligo. *J Am Acad Dermatol* 2021; **84**: 1619–1627.
- Tovar-Garza A, Hinojosa JA, Hynan LS, Pandya AG. Addition of oral minipulse dexamethasone to narrowband ultraviolet B phototherapy and

- topical steroids helps arrest disease activity in patients with vitiligo. *Br J Dermatol* 2019; **180**: 193–194.
- 36 Hamzavi I, Al-Hadidi N, Griffith J, Al-Jamal M. Role of recipient-site preparation techniques and post-operative wound dressing in the surgical management of vitiligo. *J Cutan Aesthet Surg* 2015; **8**: 79.
 - 37 Ko WC, Chen YF. Suction blister epidermal grafts combined with CO₂ Laser superficial ablation as a good method for treating small-sized vitiligo. *Dermatologic Surg* 2009; **35**: 601–606.
 - 38 Silpa-Archa N, Griffith JL, Williams MS et al. Prospective comparison of recipient-site preparation with fractional carbon dioxide laser vs. dermabrasion and recipient-site dressing composition in melanocyte-keratinocyte transplantation procedure in vitiligo: a preliminary study. *Br J Dermatol* 2016; **174**: 895–897.
 - 39 Apfelberg DB, Smoller B. UltraPulse carbon dioxide laser with CPG scanner for deepithelialization: clinical and histologic study. *Plast Reconstr Surg* 1997; **99**: 2089–2094.
 - 40 Oh CK, Cha JH, Lim JY et al. Treatment of vitiligo with suction epidermal grafting by the use of an ultrapulse CO₂ laser with a computerized pattern generator. *Dermatologic Surg* 2001; **27**: 565–568.
 - 41 Rubach BW, Schoenrock LD. Histological and clinical evaluation of facial resurfacing using a carbon dioxide laser with the computer pattern generator. *Arch Otolaryngol - Head Neck Surg* 1997; **123**: 929–934.
 - 42 Hasegawa T, Suga Y, Ikejima A et al. Suction blister grafting with CO₂ laser resurfacing of the graft recipient site for vitiligo. *J Dermatol* 2007; **34**: 490–492.
 - 43 Sun X, Qian G, Wu Y et al. Transplantation of autologous minigrafts for the treatment of stable vitiligo. *J Dermatolog Treat* 2012; **23**: 122–127.
 - 44 Kaufmann R, Greiner D, Kippenberger S, Bernd A. Grafting of in vitro cultured melanocytes onto laser-ablated lesions in vitiligo. *Acta Dermat Venereol* 1998; **78**: 136–138.
 - 45 Gupta S, Relhan V, Garg V, Sahoo B. Autologous noncultured melanocyte-keratinocyte transplantation in stable vitiligo: a randomized comparative study of recipient site preparation by two techniques. *Indian J Dermatol Venereol Leprol* 2019; **85**: 32–38.
 - 46 Lagrange S, Montaudié H, Fontas E et al. Comparison of microneedling and full surface erbium laser dermabrasion for autologous cell suspension grafting in nonsegmental vitiligo: a randomized controlled trial. *Br J Dermatol* 2019; **180**: 1539–1540.
 - 47 Lommerts JE, Meesters AA, Komen L et al. Autologous cell suspension grafting in segmental vitiligo and piebaldism: a randomized controlled trial comparing full surface and fractional CO₂ laser recipient-site preparations. *Br J Dermatol* 2017; **177**: 1293–1298.
 - 48 Altalhab S, Al Jasser MI, Mulekar SV et al. Six-year follow-up of vitiligo patients successfully treated with autologous non-cultured melanocyte-keratinocyte transplantation. *J Eur Acad Dermatol Venereol* 2019; **33**: 1172–1176.
 - 49 Bayoumi W, Fontas E, Sillard L et al. Effect of a preceding laser dermabrasion on the outcome of combined therapy with narrowband ultraviolet B and potent topical steroids for treating nonsegmental vitiligo in resistant localizations. *Br J Dermatol* 2012; **166**: 208–211.
 - 50 Chiu YJ, Perng CK, Ma H. Fractional CO₂ laser contributes to the treatment of non-segmental vitiligo as an adjunct therapy: a systemic review and meta-analysis. *Lasers Med Sci* 2018; **33**: 1549–1556.
 - 51 Manstein D, Herron GS, Sink RK et al. Fractional photothermolysis: a new concept for cutaneous remodeling using microscopic patterns of thermal injury. *Lasers Surg Med* 2004; **34**: 426–438.
 - 52 Bae JM, Hann SK. Laser treatments for vitiligo. *Med Laser* 2016; **5**: 63–70.
 - 53 Kanokrungrsee S, Chanprapaph K, Chaiyabutr C, Vachiramon V. A comparative study of combined treatment with fractional carbon dioxide and targeted ultraviolet B phototherapy for facial vitiligo. *Lasers Med Sci* 2016; **31**: 1343–1349.
 - 54 Geronemus RG. Fractional photothermolysis: current and future applications. *Lasers Surg Med* 2006; **38**: 169–176.
 - 55 Ross EV, Yashar SS, Naseef GS et al. A pilot study of in vivo immediate tissue contraction with CO₂ skin laser resurfacing in a live farm pig. *Dermatol Surg* 1999; **25**: 851–856.
 - 56 Kim WI, Kim S, Lee SH, Cho MK. The efficacy of fractional carbon dioxide laser combined with narrow-band ultraviolet B phototherapy for non-segmental vitiligo: a systematic review and meta-analysis. *Lasers Med Sci* 2021; **36**: 165–173.
 - 57 Chang HC, Lin MH, Tsai HH. Efficacy of combination therapy with fractional carbon dioxide laser and ultraviolet B phototherapy for vitiligo: a systematic review and meta-analysis. *Aesthet Surg J* 2020; **40**: NP46–NP50.
 - 58 Ghasemloo S, Gauthier Y, Ghalamkarpour F. Evaluation of using fractional CO₂ laser plus NB-UVB versus NB-UVB alone in inducing marginal repigmentation of vitiligo lesions. *J Dermatolog Treat* 2019; **30**: 697–700.
 - 59 Doghaim NN, Gheida SF, El-Tatawy RA, Mohammed Ali DA. Combination of fractional carbon dioxide laser with narrow band ultraviolet B to induce repigmentation in stable vitiligo: a comparative study. *J Cosmet Dermatol* 2019; **18**: 142–149.
 - 60 Shin J, Lee JS, Hann SK, Oh SH. Combination treatment by 10 600 nm ablative fractional carbon dioxide laser and narrowband ultraviolet B in refractory nonsegmental vitiligo: a prospective, randomized half-body comparative study. *Br J Dermatol* 2012; **166**: 658–661.
 - 61 Eşme P, Gür Aksoy G, Elçin G. No additional benefit of combining fractional carbon dioxide laser with narrow-band ultraviolet B phototherapy for vitiligo: a randomized prospective study with half-body side comparison. *Dermatol Surg* 2019; **45**: 1627–1634.
 - 62 Vachiramon V, Chaiyabutr C, Rattanaumpawan P, Kanokrungrsee S. Effects of a preceding fractional carbon dioxide laser on the outcome of combined local narrowband ultraviolet B and topical steroids in patients with vitiligo in difficult-to-treat areas. *Lasers Surg Med* 2016; **48**: 197–202.
 - 63 King YA, Tsai TY, Tsai HH, Huang YC. The efficacy of ablation-based combination therapy for vitiligo: a systematic review and meta-analysis. *J Dtsch Dermatol Ges* 2018; **16**: 1197–1208.
 - 64 Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. *Lancet* 2015; **386**: 74–84.
 - 65 Huang C, Li P, Wang B et al. Multi-factors associated with efficacy and adverse events of fractional Erbium:YAG laser-assisted delivery of topical betamethasone for stable vitiligo: a retrospective analysis. *Lasers Surg Med* 2020; **52**: 590–596.
 - 66 Gupta D, Kumari R, Thappa MH. Depigmentation therapies in vitiligo. *Indian J Dermatol Venereol Leprol* 2012; **78**: 49–58.
 - 67 Mosher DB, Parrish JA, Fitzpatrick TB. Monobenzyloxy of hydroquinone: a retrospective study of treatment of 18 vitiligo patients and a review of the literature. *Br J Dermatol* 1977; **97**: 669–681.
 - 68 Bolognia JL, Lapia BK, Somma S. Depigmentation therapy. *Dermatol Ther* 2001; **14**: 29–34.
 - 69 Kavuoosi H. Induction of depigmentation in a universal vitiligo patient with combination of cryotherapy and phenol. *J Pak Assoc Dermatol* 2009; **19**: 112–114.
 - 70 Di Nuzzo S, Masotti A. Depigmentation therapy in vitiligo universalis with cryotherapy and 4-hydroxyanisole. *Clin Exp Dermatol* 2010; **35**: 215–216.
 - 71 Kim YJ, Chung BS, Choi KC. Depigmentation therapy with Q-switched ruby laser after tanning in vitiligo universalis. *Dermatol Surg* 2001; **27**: 969–970.
 - 72 Rao J, Fitzpatrick RE. Use of the Q-switched 755 nm alexandrite laser to treat recalcitrant pigment after depigmentation therapy for vitiligo. *Dermatol Surg* 2004; **30**: 1043–1045.
 - 73 Majid I, Imran S. Depigmentation therapy with Q-Switched Nd: YAG laser in universal vitiligo. *J Cutan Aesthet Surg* 2013; **6**: 93–96.
 - 74 Al Ghamdi KM, Kumar A. Depigmentation therapies for normal skin in vitiligo universalis. *J Eur Acad Dermatol Venereol* 2011; **25**: 749–757.
 - 75 El-Mofty M, Mostafa WZ, Esmat S et al. Site-oriented depigmentation in vitiligo patients using Q-switched Nd:YAG laser (1,064/532 nm),

- cryotherapy and chemical peels: a comparative study. *DermatolTher* 2019; **32**: e13052.
- 76 Majid I, Imran S. Depigmentation with Q-switched Nd:YAG laser in universal vitiligo: a long-term follow-up study of 4 years. *Lasers Med Sci* 2017; **32**: 851–855.
- 77 Thissen M, Westerhof W. Laser treatment for further depigmentation in vitiligo. *Int J Dermatol* 1997; **36**: 386–388.
- 78 Komen L, Zwertbroek L, Burger SJ *et al.* Q-switched laser depigmentation in vitiligo, most effective in active disease. *Br J Dermatol* 2013; **169**: 1246–1251.
- 79 Njoo MD, Vodegel RM, Westerhof W. Depigmentation therapy in vitiligo universalis with topical 4-methoxyphenol and the Q-switched ruby laser. *J Am Acad Dermatol* 2000; **42**(5 Pt 1): 760–769.
- 80 van Geel N, Depaep L, Speeckaert R. Laser (755 nm) and cryotherapy as depigmentation treatments for vitiligo: a comparative study. *J Eur Acad Dermatol Venereol* 2015; **29**: 1121–1127.
- 81 Boukari F, Lacour JP, Ortonne JP *et al.* Laser-assisted depigmentation for resistant vitiligo: a retrospective case series with long-term follow-up. *J Eur Acad Dermatol Venereol* 2014; **28**: 374–377.